Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

41.10
+1.854.71%
Post-market: 41.210.1100+0.27%19:59 EDT
Volume:14.82M
Turnover:610.54M
Market Cap:47.88B
PE:68.50
High:42.02
Open:40.22
Low:40.12
Close:39.25
52wk High:42.02
52wk Low:18.83
Shares:1.17B
Float Shares:1.09B
Volume Ratio:3.10
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:6.18
PE(LYR):33.97

Loading ...

Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says

MT Newswires Live
·
6 hours ago

Teva Pharmaceutical on Track for Highest Close Since February 2017

Dow Jones
·
6 hours ago

Teva's Weltruza Seen as Launch-Execution Story After Clean Label, Oppenheimer Says

MT Newswires Live
·
7 hours ago

Oppenheimer Adjusts Teva Pharmaceutical Industries PT to $52 From $50, Maintains Outperform Rating

MT Newswires Live
·
7 hours ago

Pharma Stocks Jump With Novavax up 12%, Moderna up 6%

Tiger Newspress
·
Yesterday

Movement Alert|Teva Pharmaceutical Rises 5.05% in Regular Trading, FDA Approves WELTRUZA for Schizophrenia

Market Focus
·
Yesterday

Bank of America Securities Sticks to Its Buy Rating for Teva (TEVA)

TIPRANKS
·
Yesterday

Teva Pharmaceutical Industries Says FDA Approved WELTRUZA for Schizophrenia in Adults

MT Newswires Live
·
Yesterday

Teva announces FDA approval for Weltruza

TIPRANKS
·
Yesterday

Teva call volume above normal and directionally bullish

TIPRANKS
·
Oct 08

Scotiabank Keeps Their Buy Rating on Teva (TEVA)

TIPRANKS
·
Oct 02

Teva: Additional Analyses Found That Common Concurrent Psychiatric Conditions Did not Negatively Impact Ecopipam's Efficacy or Safety

THOMSON REUTERS
·
Oct 02

Update: Teva, Samsung Bioepis Partner to Develop, Commercialize Biosimilar Candidates

MT Newswires Live
·
Oct 02

TD Cowen Initiates Teva Pharmaceutical Industries at Buy With $55 Price Target

MT Newswires Live
·
Oct 01

Teva initiated with a Buy at TD Cowen

TIPRANKS
·
Oct 01

Teva, Samsung Bioepis Partner to Develop and Commercialize Biosimilar Candidates

MT Newswires Live
·
Oct 01

Press Release: TAPI (Technology & API Services) Names Serge Rogasik CEO to Lead Next Chapter of Growth and Competitiveness

Dow Jones
·
Oct 01

NYSE Order Imbalance 18799.0 Shares on Buy Side

THOMSON REUTERS
·
Sep 30

Teva Reports FDA Approval for Degevma

MT Newswires Live
·
Sep 29

Teva announces FDA approval of Degevma as a biosimilar to Xgeva

TIPRANKS
·
Sep 29